Amgen Inc. (NASDAQ:AMGN) Shares Bought by Hudson Value Partners LLC

Hudson Value Partners LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 7.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,856 shares of the medical research company’s stock after acquiring an additional 1,071 shares during the quarter. Amgen accounts for about 1.5% of Hudson Value Partners LLC’s holdings, making the stock its 24th biggest position. Hudson Value Partners LLC’s holdings in Amgen were worth $4,133,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AMGN. AMF Tjanstepension AB raised its stake in shares of Amgen by 16.9% during the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after buying an additional 17,387 shares during the last quarter. Swedbank AB increased its position in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after purchasing an additional 5,751 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Amgen during the 3rd quarter worth about $100,000. Convergence Financial LLC purchased a new stake in Amgen during the 3rd quarter worth about $204,000. Finally, Allworth Financial LP increased its position in Amgen by 3.2% during the 3rd quarter. Allworth Financial LP now owns 25,033 shares of the medical research company’s stock worth $8,066,000 after purchasing an additional 785 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AMGN. Leerink Partners dropped their price objective on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Wolfe Research began coverage on Amgen in a research report on Friday, November 15th. They set a “peer perform” rating for the company. Piper Sandler lifted their price objective on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Deutsche Bank Aktiengesellschaft lowered their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $314.09.

Amgen Stock Up 1.7 %

NASDAQ AMGN opened at $303.01 on Friday. The stock has a market cap of $162.78 billion, a PE ratio of 40.13, a P/E/G ratio of 2.58 and a beta of 0.56. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The business has a 50 day moving average price of $276.27 and a two-hundred day moving average price of $300.40. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, sell-side analysts predict that Amgen Inc. will post 20.6 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.14%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.